BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Welcome to the 4th In Vivo Cell Engineering and Gene Editing S
 ummit\, the premier event dedicated to enhancing the next frontier of in 
 vivo cell and gene approaches from research to clinic. This summit provid
 es you with exclusive insights into the latest IND enabling data\, regula
 tory and inter-governmental processes and requirements\, best-in-class de
 livery technologies\, cutting-edge innovations in editing and engineering
  and insights into effective clinical trial design from industry leaders 
 including Capstan Therapeutics\, Editas Medicine\, Carisma Therapeutics\,
  AbbVie\, Intellia Therapeutics\, Umoja Biopharma and many more!\n\nThe i
 n vivo approach is revolutionizing the cell and gene space. These ground-
 breaking technologies promise more efficient\, accessible and cost-effect
 ive therapies and paving the way for the future of cell and gene treatmen
 ts. With leading companies entering the clinic and investments and collab
 orations unfolding\, the potential of in vivo therapies to treat a variet
 y of indications including oncology\, genetic and rare diseases is now fr
 ont and centre.\n\nGain exclusive access to ground-breaking discoveries a
 nd networking opportunities to propel your pipelines to new heights!\n\nU
 RLs:Brochure: https://go.evvnt.com/2884100-0?pid=185Tickets: https://go.e
 vvnt.com/2884100-1?pid=185\n\nTime: 8:00 AM - 5:00 PM\n\nSpeakers: Cecile
  Bauche\, Founder and Chief Scientific Officer\, Alaya.bio\, Adrian Bot\,
  Founding Chief Scientific Officer and Executive Vice President - Researc
 h and Development\, Capstan Therapeutics\, Delai Chen\, Director - Nanopa
 rticle Formulation\, Beam Therapeutics Inc.\, Gilmore O'Neill\, President
  and Chief Executive Officer\, Editas Medicine\, Michael Klichinsky\, Co-
 Founder and Chief Scientific Officer\, Carisma Therapeutics\, Laura Green
  Director\, Program Management\, Umoja Biopharma\, Daniel Getts\, Chief E
 xecutive Officer\, Myeloid Therapeutics\, Robert Hofmeister\, Chief Scien
 tific Officer\, Myeloid Therapeutics\n
DTEND:20250605T170000
DTSTAMP:20260512T220334Z
DTSTART:20250603T080000
LOCATION:Hilton Boston Logan Airport\, One Hotel Drive\, Boston\, Massachu
 setts\, 02128\,
SEQUENCE:0
SUMMARY:Welcome to the 4th In Vivo Cell Engineering and Gene Editing Summi
 t\, the premier event dedicated to enhancing the next frontier of in vivo
  cell and...
UID:8561f527-06fb-48de-9578-e546172c700f
END:VEVENT
END:VCALENDAR